Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Preferred Stock Liabilities (2016 - 2019)

United Therapeutics' Preferred Stock Liabilities history spans 8 years, with the latest figure at $8.4 million for Q2 2019.

  • For Q2 2019, Preferred Stock Liabilities fell 56.25% year-over-year to $8.4 million; the TTM value through Jun 2019 reached $8.4 million, down 56.25%, while the annual FY2018 figure was $19.2 million, 0.0% changed from the prior year.
  • Preferred Stock Liabilities for Q2 2019 was $8.4 million at United Therapeutics, down from $19.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $20.4 million in Q1 2015 and bottomed at $8.4 million in Q2 2019.
  • The 5-year median for Preferred Stock Liabilities is $16.1 million (2015), against an average of $15.2 million.
  • The largest annual shift saw Preferred Stock Liabilities crashed 66.6% in 2015 before it soared 76.15% in 2017.
  • A 5-year view of Preferred Stock Liabilities shows it stood at $11.1 million in 2015, then fell by 1.8% to $10.9 million in 2016, then skyrocketed by 76.15% to $19.2 million in 2017, then changed by 0.0% to $19.2 million in 2018, then crashed by 56.25% to $8.4 million in 2019.
  • Per Business Quant, the three most recent readings for UTHR's Preferred Stock Liabilities are $8.4 million (Q2 2019), $19.2 million (Q1 2019), and $19.2 million (Q4 2018).